Mediclinic released their interim results for the six months ended 30 September 2018 on the 15th of November 2018. Revenue for the reporting period declined by 1% (2% increase in constant currency terms), adjusted earnings per share decreased by 9% to 10.3 pence per share and the group maintained its interim dividend at 3.2 pence per share.
The group expects modest revenue growth from its Swiss operations for the remainder of the 2019 financial year. Mediclinic Southern Africa’s margins is expected to be in line with prior periods. The group expects the Middle East division to deliver slightly improved margins due to additional bed capacity coming online.
Click here to download the full report.